{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.0","upperLimit":"59.7","value":"53.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"295"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants who achieve a best response of PR or better including stringent complete response (sCR), VGPR and PR assessed with IMWG Criteria, after the start of the study treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.","id":"OG000","title":"Ixazomib + Lenalidomide + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set, defined as all participants who were enrolled into the study and who receive at least one dose of ixazomib.","reportingStatus":"POSTED","timeFrame":"Up to 36 months as a maximum","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}